#AAV_Gene_Therapy
LightNews LightNews
xsbrt.bsky.social
Myth: AAV is harmless — not always. Quick win: design trials with long oncogenicity monitoring and clear stopping rules to reduce holds and restore trust. Full breakdown → https://future.xsbrt.com/GeneTherapyRiskRegulationTrustFuture Replies/saves welcome. #AAV_gene_therapy
February 7, 2026 at 12:06 AM
newsen.bsky.social
Andelyn Biosciences Collaborates with Tern Therapeutics to Tackle CLN2 Batten Disease with AAV Gene Therapy#USA#Columbus#Andelyn_Biosciences#AAV_Gene_Therapy#CLN2_Batten_Disease
Andelyn Biosciences Collaborates with Tern Therapeutics to Tackle CLN2 Batten Disease with AAV Gene Therapy
Andelyn Biosciences teams up with Tern Therapeutics for late-stage manufacturing of AAV gene therapy aimed at curing CLN2 Batten disease, offering hope for affected children.
third-news.com
September 3, 2025 at 12:27 PM
newsen.bsky.social
Viralgen Enters Clinical Development Network to Tackle Rare Diseases#Spain#San_Sebastián#Viralgen#AAV_Gene_Therapy#Orphan_Therapeutics_Accelerator
Viralgen Enters Clinical Development Network to Tackle Rare Diseases
Viralgen partners with Orphan Therapeutics Accelerator to enhance AAV gene therapy efforts for ultra-rare diseases, aiming to streamline manufacturing processes.
third-news.com
May 14, 2025 at 12:39 PM
newsen.bsky.social
Azenta Life Sciences and Form Bio Partner to Revolutionize Gene Therapy Development#USA#Burlington#AAV_Gene_Therapy#Azenta_Life_Sciences#Form_Bio
Azenta Life Sciences and Form Bio Partner to Revolutionize Gene Therapy Development
Azenta Life Sciences teams up with Form Bio to enhance AAV gene therapy, utilizing advanced sequencing and AI analysis for faster, safer solutions.
third-news.com
May 13, 2025 at 8:22 PM
newsen.bsky.social
Viralgen Partners with Trogenix to Propel AAV Gene Therapy for Glioblastoma#Spain#San_Sebastián#Viralgen#AAV_Gene_Therapy#Trogenix
Viralgen Partners with Trogenix to Propel AAV Gene Therapy for Glioblastoma
Viralgen joins forces with Trogenix to advance AAV gene therapy for glioblastoma, enhancing manufacturing and accelerating clinical trials.
third-news.com
May 6, 2025 at 2:05 PM
newsen.bsky.social
Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting#Avirmax_Biopharma#AAV_Gene_Therapy#Dry_AMD
Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting
Avirmax Biopharma is set to make a significant impact at the 2025 ARVO meeting with multiple presentations focused on ocular gene therapy advancements through its proprietary technologies.
third-news.com
April 23, 2025 at 8:48 PM